MAP2K7 and acute lymphoblastic leukemia: Here, we clearly show that the synergistic efficacy observed in ALL cells co-treated with pevonedistat plus SEL is due to inhibition of the MEK/ERK pathway leading to increased activity of the pro-apoptotic BIM protein.